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We have previously reported (1)  that  thrombin-induced platelet aggregation and 
release is enhanced in the presence of complement. Only components C3, C5, C6, C7, 
C8,  and  C9  are  required.  No  known  activating  mechanism  of the  classical  or 
alternative  pathways  is  involved  in  this  reaction.  This  system  enters  the  known 
complement sequence at the C3 stage. Because the sequence of addition of thrombin 
and C3-C9 was important, we postulated that the thrombin initially reacted with the 
thrombin  receptor  on  the  platelet  surface,  and  then  activated  the  complement 
sequence directly on the platelet surface. In the present communication we will make 
three major points. First, we will present data which demonstrate that if complement 
is activated by an enzyme such as trypsin for which the platelet has no receptor, no 
enhancement of platelet function is obtained subsequent to the addition of comple- 
ment.  Second, when complement is activated on the  platelet  surface by thrombin, 
C5b-9 complexes are produced which can be eluted from the platelet membrane and 
can  be  demonstrated  physicochemically as  33S  multimolecular  complexes.  These 
multimolecular complexes can be visualized ultrastructurally. Third, we will present 
data demonstrating that the complement-induced enhancement of platelet function 
may  be  mediated  via  the  arachidonic  acid  transformation  pathway  because  it  is 
inhibited by known inhibitors of cyclo-oxygenase such as aspirin and indomethacin. 
Materials and Methods 
Preparation of Washed Platelets and SubceUular Fractions.  A  suspension of human platelets was 
obtained using the Ardlie buffer system  modified  as  previously described  (1).  Platelet  mem- 
branes were prepared previously as described (2). 
Preparation of Aluminum  Hydroxide-absorbed Serum.  Fresh  human  serum  was  absorbed  with 
aluminum hydroxide as previously described  (3) under conditions that were shown to remove 
prothrombin but not to inactivate complement. Serum was considered to be prothrombin-free 
if no  clot  was  formed  after  incubation  with  fibrinogen  (1.5  mg/ml)  for  48  h.  Assays  were 
performed to measure the activity of whole complement and components of both the classical 
and alternate mechanism as previously described (3). 
Preparation of Complement Components.  C3  (4), C4  (5), (35  (6), C6, C7  (7), C8  (8), and C9  (9) 
were  prepared  by  methods  described  earlier.  In  addition,  in  some  experiments  purified 
complement components prepared by Cordis Laboratories Inc., Miami, Fla. were utilized. 
Radiolabeling of the  Fifth  Component of Complement (C5).  C5  was  labeled  with  I2sI  by  the 
method of McConahey and Dixon  (10). The sp act was -100,000 cpm/#g. 
Platelet Aggregation.  Assays for platelet aggregation were performed in a Payton dual channel 
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aggregometer using a  Riken Denshi recorder (Payton Associates Inc., Buffalo, N. Y.). Platelets 
were suspended  at 200,000/#1  in Ardlie II buffer in which bicarbonate was replaced with Tris 
(1). All reagents added to the washed platelets were dialyzed before use with cacodylate buffer, 
pH 7.4,  a buffer shown to be optimal for aggregation of washed platelets (11). Highly purified 
human  thrombin  (2.05  U/p.g)  was  prepared  and  kindly supplied  by  Dr. John  Fenton,  New 
York State Department  of Health, Albany, N. Y. 0.1  U  (50 ng)  in  10 ~l was added  to 0.3 ml 
washed platelets. Trypsin  (0.245  U/#g) was purchased  from Worthington  Biochemical Corp., 
Freehold, N. J. Various concentrations in 10-#1 vol were added to 0.3 ml washed platelets. The 
mixture was stirred  for 5  min,  then twice the concentration  of soybean  trypsin  inhibitor was 
added  (Calbiochem-Behring Corp., American Hoechst Corp., San Diego, Calif.). 
Release of[l#C]Serotonin.  Platelets suspended  in plasma were labeled with [~4C]serotonin by 
the method of Valdorf-Hansen and Zucker (12).  The radiolabeled platelets were then washed 
in  the  usual  way  (1,  13).  For the experiment,  0.3  ml of the washed  platelet  suspension  was 
utilized to which  10-~1 aliquots of various reagents were added.  Aggregation was recorded for 
5 min, then the tube was centrifuged and the supernate removed. 14C was counted in both the 
supernate and the cell button  in a  Packard  Liquid Scintillation Counter (Packard  Instrument 
Co., Inc., Downers Grove, Ill.) and the percentage of release was calculated. 
Preparation  of Complement  Source Lacking  Anti-Thrombin  III  or Albumin.  Antibodies  to  anti- 
thrombin III and anti-albumin  (Behring Diagnostics, American Hoechst Corp., Somerville, N. 
J.)  were  conjugated  to  Sepharose  4B  (Pharmacia  Fine  Chemicals,  Div.  of Pharmacia,  Inc., 
Piscataway,  N. J.) by the method of Cuatrecasas  (14)  and 0.2 ml of the conjugated sepharose 
was added to  1 ml of aluminum  hydroxide-absorbed  serum. The tube containing the mixture 
was clipped onto a  rotator and was allowed to rotate for 60 min at 4°C. The tubes were then 
centrifuged and the supernatant  serum was recovered.  10 #1 of the serum absorbed  either with 
anti-anti-thrombin  III or with anti-albumin  was added  to 0.3 ml platelet suspension  after the 
addition of 0.1  U  thrombin. 
Preparation  of Whole Platelet-Thrombin-C5b-9  Complexes.  5 U  of thrombin was added  to 6  ml 
platelet suspension  (200,000  platelets/~l).  To this mixture was added  0.2 ml each of C3, C6, 
C7, C8, and C9; and 0.3 ml [12SI]C5 containing  1.4  ×  10  7 cpm. A second tube contained 6 ml 
platelets, 5 U  of thrombin and 0.4 ml of aluminum hydroxide-absorbed serum as the source of 
complement. A similar amount of [x2SI]C5 was added to the mixture. Two sets of controls were 
used.  One contained  the same reagents as the test sample but  included heparin  at  10 U/ml. 
The  second  control  included  platelets  and  complement  components  including  [12SI]C5, but 
contained no thrombin. 
Samples  were  incubated  at  37 °  for  45  min  with  constant  shaking.  The  tubes  were  then 
centrifuged for  15  min at  23,300 g. The supernate  was removed and  the platelet button  was 
washed five times with phosphate-buffered  saline, pH  7.4  (PBS).  Each centrifugation was for 
15 min at 23,300 g. After the last centrifugation, 0.3 ml PBS containing 0.1% Triton X-100 was 
added  to  the cell button.  The  samples  were then  frozen and  thawed  five times,  and  finally 
centrifuged at 43,500 g for 2 h, and the supernate recovered. 
Preparation  ofPlatelet Membrane-Thrombin-C5b-9  Complexes.  Platelet  membranes  from  7 U  of 
blood were utilized.  1 ml modified Ardlie II buffer (1) was added to the membrane button with 
thorough mixing, and 0.25 ml was then aliquoted into each of four tubes.  3.75 ml of the same 
buffer was added to each tube. To two tubes was added  10 U  thrombin and 0.7 ml aluminum 
hydroxide-absorbed  serum  further absorbed  with  anti-anti-thrombin  III  (Results)  containing 
0.5 ml [12SI]C5 (1.8  ×  10  7 cpm). To the other two tubes was added  10 U  thrombin and 0.4 ml 
each of C3, C6, C7, C8, and C9;  and 0.5 ml [12SI]C5. Heparin  at  10 U/ml was added  to one 
tube of each pair. In some experiments, instead of the heparin-containing control, control tubes 
contained  platelet membranes  and  aluminum  hydroxide-absorbed  serum or purified comple- 
ment components and  [12SI]C5, but no thrombin. 
All  four  tubes  were  incubated  at  37 °  for  30  min  with  rotation.  The  samples  were  then 
centrifuged  for  3  h  at  37,500  g.  The  cell  button  was  washed  three  times  in  PBS,  each 
centrifugation being 2 h  at  121,000 g. Elution of the putative C5b-9 complexes was performed 
according to the method of Biesecker et al.  (15).  After the final wash,  1.0 ml of 0.05  M  Tris- 
acetate buffer, pH 8.9, containing  10% deoxycholate (DOC) 1 (Sigma Chemical Co., St. Louis, 
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Mo.) was added to the membranes. After a thorough mixing process, the mixture was allowed 
to stand at room temperature for 2 h  and was then centrifuged at  121,000  g  for 3.5 h.  The 
supernate was removed and 0.7 ml was applied to a  Rio-Gel A15 m  (Bio-Rad Laboratories, 
Richmond, Calif.) column  (23.5  ×  1 cm) equilibrated in 0.05 M  Tris-acetate buffer, pH 8.6, 
containing 2% DOC. 0.5 ml fractions were collected and 0.3 ml of the peak tube from the first 
peak of radioactivity to elute from the column was subjected to density-gradient ultracentrif- 
ugation. 
Sucrose Density-Gradient Ultracentrifugation.  Two methods of sucrose density-gradient ultracen- 
trifugation  were  employed.  10-40%  linear,  sucrose  density  gradients  were  prepared  with 
barbitol-buffered saline, pH 7.4, ionic strength 0.15, in 5-ml cellulose nitrate tubes; or 10-50% 
linear gradients were prepared with 0.05 M  Tris-acetate buffer, pH 8.6,  containing 1% DOC 
(15).  The sample size was 0.2-0.3  ml and centrifugation was performed in a  Beckman  50.1 
rotor (Beckman Instruments Inc., Science Essentials Co., Mountainside, N.J.) for 18 h at 96,000 
g.  Seven-drop  fractions  were  obtained  with  a  Buchler  (Buchler  Instruments  Div.,  Searle 
Diagnostics, Fort Lee, N. J.)  piercing unit  and counted  in a  Searle gamma counter  (model 
1185, Searle Radiographies Inc., Des Plaines, I11.). 
Preparation of C5b-9 Complexes  for Electron Microscopy.  Samples of the peak tubes  from  the 
appropriate area of the density gradients were pooled and  dialyzed overnight against Tris- 
acetate buffer,  pH  8.6,  containing  1%  DOC.  Appropriate dilutions were  prepared and  the 
samples were stained with 2% sodium silicotungstate, then directly applied to a collodion-and- 
carbon-coated  grid  and  viewed  in  a  Philips  301  Electron  Microscope  (Philips  Electronic 
Instruments, Inc., Mahwah, N. J.). 
Treatment of Platelets with Aspirin and Indomethacin.  Two inhibitors of cyclo-oxygenase were 
used in this study, namely, aspirin (acetylsalicylic acid) and  indomethacin. Both drugs were 
obtained from Sigma Chemical Co. They were dissolved in ethanol, then diluted to the desired 
concentration with Ardlie II buffer. Two methods of treatment were employed. First, platelets 
were pretreated with the drug. For this treatment aspirin (100/.tM) or indomethacin (28/~M) 
was added to the platelet-rich plasma and  the mixtures were incubated at  37 °  for 30  min. 
Platelets were then washed in the usual manner.  The second method was to have the drugs 
present in the reaction mixture, and for this method, the same final concentration of the drugs 
was employed. 0.3 ml washed platelet suspension was pipetted into the aggregometer cuvette. 
An appropriate amount of the drug was added in a  I0-#1 vol then allowed to incubate for 15 
min at 37 ° before either thrombin alone or thrombin followed by a source of complement was 
added. 
In  Vivo Aspirinization of Platelets.  Normal  volunteer donors  ingested 2  ×  300  mg aspirin 
tablets ~ 10 h before donating blood to be used for the platelet preparation. 
Results 
[14C]Serotonin Release Mediated by Trypsin and Thrombin.  As shown  in Fig.  1,500  ng 
(0.12  U)  of trypsin induced 33%  release of serotonin.  This  finding agrees with  that 
obtained by Ganguly (16). The addition of C3, C5, C6, C7, C8, and C9 caused very 
little additional release of serotonin. On  the other hand,  50  ng  (0.1  U)  of thrombin 
induced 20% release of serotonin, but the addition of the same purified complement 
components, increased serotonin release threefold (62%). 
The Effect on Complement-dependent Thrombin-induced Serotonin Release of Removal of Anti- 
Thrombin IIIfrom the Complement Source.  It has been previously reported (17) that anti- 
thrombin III inhibits the C5b, 6, 7 complex. Therefore, it was of interest to determine 
the effect  of the  removal of this  inhibitor on  the complement-dependent  serotonin 
release  reaction.  Aluminum  hydroxide-absorbed serum  was  further  absorbed  with 
antibody to anti-thrombin III conjugated to Sepharose. A second aliquot of the serum 
was absorbed with anti-albumin conjugated to Sepharose under identical conditions 
to serve as the control. The results of three separate experiments are shown in Fig. 2. 
Removal of anti-thrombin III caused an ~  15-20% increase in complement-dependent 
thrombin-mediated  release  of serotonin  over  that  obtained  with  the  control  anti- 636  COMPLEMENT AND PLATELET FUNCTION 
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FIG.  1.  The effect of complement on trypsin- and thrombin-induced release of platelet serotonin. 
C3-9, highly  purified C3, C5, C6, C7, C8, and C9. (A) and (B) indicate sequence of addition. 
albumin-absorbed serum. 
Physicochemical Demonstration of the Presence of C5b-9 Complexes on the Platelet Surface; the 
Formation and Uptake Mediated by Thrombin.  In the initial experiments a suspension of 
whole platelets  was utilized.  The platelet  suspension was incubated with  thrombin 
and  either purified  C3,  C5,  C6,  C7,  C8, and  C9 or aluminum hydroxide-absorbed 
serum  as  the  source of complement•  Radioactively labeled  C5  was  added  to each. 
After a  thorough washing procedure,  the  putative complexes were eluted  from the 
platelets with Triton X-100 plus freezing and thawing, and the eluate was subjected 
to density-gradient ultracentrifugation. As shown in Figs. 3 A and 3 B, no radiolabeled 
C5 was found in the 33S region which would have indicated C5b-9 complex forma- 
tion  (15,  18). Instead, 90% of the C5  in  the case of aluminum hydroxide-absorbed 
serum and 50% when the purified components were utilized was found in a  position 
midway  between  the  two  markers,  sheep  hemoglobin  (4-5S)  and  [gG(7S).  This 
observation suggested that the C5 was cleaved by some platelet-associated proteolytic 
enzyme because native C5 has an s of 8.7S. 
To overcome this probable proteolytie degradation of C5, a similar experiment was 
performed in which a preparation of isolated platelet membranes was used instead of 
whole platelets.  Figs.  4 and 5 demonstrate the results of such experiments. 
Fig.  4  demonstrates  the  results  of molecular-sieve  chromatography on  Bio-Gel 
A15m of the platelet eluate. The peak tube from the first  peak (arrow) to elute from 
the column was subjected to sucrose density-gradient ultracentrifugation. The results 
of this  experiment  are  shown  in  Fig.  5.  Complex  formation  was  indicated  when 
[12~I]C5 eluted  in  the  heavy part  of the  gradient.  Two peaks  of radioactivity were 
identified. The heavier peak had an s of 33S and the lighter peak, of 29S. A similar 
result  was  obtained  whether  the  source of complement was  aluminum  hydroxide- MARGARET J.  POLLEY  AND RALPH L.  NACHMAN 
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FIG. 2.  The effect of removal of anti-thrombin  III from the complement source on thrombin- 
induced  release of platelet serotonin. Th,  thrombin;  AIS, fresh human  serum absorbed  with 
aluminum  hydroxide;  R-Alb,  further  absorbed  wKh anti-albumin;  R-anti-Th  III, AIS further 
absorbed with antibody to anti-thrombin  III (A) and (B) indicate sequence of addition. 
absorbed serum or purified components C3, C5, C6, C7, C8, and C9. 
Morphological Demonstration of C5b-9 Complexes Eluted from  the Platelet Membrane. Ap- 
propriate fractions from the sucrose density gradient were dialyzed to remove sucrose, 
then stained and prepared for electron microscopy. The material with a sedimentation 
rate  of 33S  was  a  suspension  of lesions  (Fig.  6).  It  has  recently  bee  n  reported  that 
complement-dependent  lesions  previously seen on various cell  types were dimers  of 
the C5b-9 complex with a sedimentation rate of 33.5S (15). The material which eluted 
from the density gradient 33S peak was morphologically identical to the C5b-9 dimer 
previously reported  (15).  Some similar structures were also seen in the material  that 
eluted at 29S. 
No complexes were demonstrable  in  controls  lacking  thrombin  or in  the  control 
samples containing heparin. 
Inhibition of the Complement-mediated, Thrombin-dependent Platelet Function by Drugs. The 
effect of aspirin and indomethacin on the complement-dependent  release of serotonin 
was determined in two ways. First, platelets in plasma were incubated with the drugs 
and then the platelets were washed free of the drugs then treated with thrombin with 
and  without  purified  components  C3-C9.  As  shown  in  Fig.  7,  aspirin  at  100  #M 
inhibited  the  complement-induced  enhancement  of serotonin  release.  However,  in- 
domethacin  (28 #M)  had little or no effect. The second method of treatment  was to 
treat  the  washed  platelets  with  the  drugs,  then  to  add  either  thrombin  alone  or 
thrombin  together  with  complement  when  the  drugs  were  still  present.  Fig.  8 638 
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demonstrates  the  results  of two  such  experiments.  Both  aspirin  and  indomethacin 
inhibited  the  complement  effect.  Neither  drug  caused  inhibition  of the  thrombin- 
mediated  release in the absence of complement  (Figs.  7 and 8). 
In  two  separate  experiments,  ingestion  of aspirin  by  the  platelet  donor  inhibited MARGARET J.  POLLEY  AND  RALPH  L  NACHMAN  639 
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F=c.  4.  Molecular-sieve chromatography of eluate obtained  from platelet  membranes incubated 
with thrombin and complement. 0.7  ml of the eluate was applied to a 23.5  ×  1 cm column of Bio- 
Gel Al5m. 0.5-ml fractions were collected.  0.3 ml of the peak tube from the first peak to elute from 
the column (arrow) was subjected to density-gradient uhracentrifugation. 
the  thrombin-mediated  complement enhancement  of serotonin  release but  had  no 
effect on the thrombin-mediated release in the absence of complement. 
Discussion 
The present  study was prompted  by several previous observations.  In  an  earlier 
communication (1) we demonstrated the effect of complement on thrombin-mediated 
platelet aggregation and release. As a result of these observations, we postulated that 
thrombin  first  reacts  with  the  thrombin  receptor  at  the  platelet  surface  and  then 
activates complement.  To  support  this  supposition  we  looked  for another  enzyme 
which induces platelet aggregation and release and which activates complement but 
for which the platelet has no receptor. Such an enzyme is trypsin. As demonstrated in 
the present study,  trypsin-mediated platelet  function  is little affected subsequent  to 
the addition of complement. These observations strengthen the premise that binding 
of the complement-activating enzyme to the platelet membrane is a necessary step for 
the enhancement effect. A second observation made in our earlier studies (1) indicated 
that  complement  components  C3,  C5,  C6,  C7,  C8,  and  C9  were  required  for 
complement-induced  enhancement  of thrombin-mediated  platelet  function.  It  ap- 
peared  probable  that  C5b-9  complexes  were  forming  on  the  platelet  membrane. 
Attempts  were  made,  therefore,  to elute  the  putative complexes  from  the  platelet 
membrane by a  modification of the  method previously described  for the elution  of 640  COMPLEMENT AND PLATELET FUNCTION 
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Flc.  5.  Sucrose  density ultracentrifugation of sample from Bio Gel A l5m column. 10-50% linear 
sucrose gradient containing 1% DOC was employed. (O), []2SI]C5; (O), native [125I]C5. Fractions 
were counted until statistical significance was achieved. 
C5b-9 complexes from platelets (19).  Elution of radiolabeled C5 from whole platelets 
in six separate experiments revealed that 50-80% of the radioactive material appeared 
in  a  position  on  the  density  gradient,  midway  between  hemoglobin  (4.5S)  and 
IgG(7S). Thus, it appeared that native C5, which has a  sedimentation rate of 8.7S, 
was cleaved by some platelet-associated proteolytic enzymes. 
Previous  studies  by Weksler  and  Coupal  (20)  have demonstrated  that  a  human 
platelet granule protease cleaves C5 in plasma to generate a chemotactic fragment. It 
is not  known whether the proteolytic cleavage obtained in this study was the same. 
The  nature  of the  low  molecular  weight  material  has  not  been  determined.  The 
sedimentation rate does not correspond to the molecular weight of C5b  (180,000)  or 
C5a  (11,000).  It is  presumably material resulting  from further cleavage of the C5b 
molecule. This low molecular weight material might correspond to one or more of the 
fragments cleaved from the a-chain of C5 by trypsin (21).  One fragment has an tool 
wt of ~33,000 and a second of ~22,000.  Both fragments originate from the same end 
of the C5 a-chain. Removal of the larger of the two results in generation of C5 inter 
a-flIII; removal of the smaller results in generation of C5 inter a-flII. 
In  an  attempt  to  obviate  the  platelet  enzymatic  activity, experiments  were  per- 
formed with  isolated,  washed  platelet  membranes. After incubation  with  thrombin 
and complement, an eluate of the platelet membrane was prepared utilizing DOC by 
a  recently  described  method  (15).  The  eluate  was  subjected  to  molecular-sieve 
chromatography and  then  an  appropriate sample was applied  to a  sucrose density 
gradient.  After  ultracentrifugation,  two  peaks  of radioactivity  were  obtained.  The 
material  eluting  at  33S  was  shown  to  be  morphologically  identical  to  the  C5b-9 
dimer  previously described  (15,  22).  A  second  peak of radioactivity  (29S)  to  elute 
from the gradient may have represented incomplete C5b-9 dimers or complexes which 
had dissociated and reassociated during the ultracentrifugation.  These observations MARGARET J.  POLLEY  AND  RALPH  L.  NACHMAN  641 
Ftc.  6.  Electron microscopical analysis of fractions from density gradient depicted in Fig.  5. The 
fractions were dialyzed  to remove sucrose, stained  with 2%  sodium silicotungstate, then applied 
directly  to  a  grid  coated  with collodion  and  carbon.  (A),  ×  84,000.  (B),  X  224,000.  The black 
square in  (A)  indicates the area shown in  (B).  The micrographs illustrate a  suspension of C5b-9 
dimers, some of which are settled flat on the grid; others are seen in a side view. The arrows indicate 
typical dimers of the C5b-9 complex which are settled flat on the grid. 642  COMPLEMENT AND PLATELET FUNCTION 
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C9. Platelets were pretreated with the drugs which were then washed away (Results). 
agree with our previous report  (3)  that  ultrastructural  lesions could be seen on the 
surface of platelets which had interacted with thrombin and complement. 
Thus,  we  have  identified  by sucrose  density  ultracentrifugation  the  presence  of 
C5b-9 complexes in an eluate from platelets which had interacted with thrombin and 
complement. The complexes were identified both physicochemically and morpholog- 
ically. Previously, thrombin-mediated uptake of C3 and C5 was demonstrated utiliz- 
ing radiolabeled components and morphologically using ferritin as a  marker (t). The 
latter  (1,  3)  together with  the  present  study  demonstrate  that  thrombin  mediates 
uptake of C3 and C5b-9 dimers by the platelet membrane and the presence of these 
complement components leads to a pronounced enhancement of platelet  function. 
We have earlier shown (1) that the platelet membrane is an integral component of 
this  system,  neither  cellular  uptake  of C3  and  C5  nor  ultrastructural  membrane- 
bound lesions could be demonstrated when the platelets were substituted for by either 
erythrocytes or  leukocytes.  Because  activating  components  of either  the  classic  or 
alternative  pathways  of complement  are  not  required,  this  third  mechanism  of 
activation of complement differs from the two major pathways previously described. 
A  working  concept  of the  C5  convertase  system  is  indicated  in  Fig.  9.  Whereas 
C4b,2a,3b is C5 convertase of the classic pathway and C3b,Bb,P is the C5 convertase 
of the  alternative  pathway,  (25  convertase of this  thrombin-dependent  pathway is 
composed of thrombin,  C3b,  and  the  platelet  membrane.  The  need  for C3  in  the 
thrombin-induced (25 convertase is surprising because it is known that thrombin will MARGARET  J.  POLLEY  AND  RALPH  L.  NACHMAN  643 
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FIo.  8.  The effect of aspirin and indomethacin on thrombin-induced release of platelet serotonin 
in "the presence and absence of complement when the drugs are present in the reaction mixture 
(Results). 
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FIo.  9.  Diagrammatical representation of C5  convcrtase  produced by  various mechanisms of 
activation; C4b,2a,3b by the classical mechanism; C3b,Bb,P by the alternative mechanism; CSb, 
thrombin, platelet membrane by the mechanism described in this paper. Illustration modified from 
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directly cleave C5 (24). However~ the cleavage of C5 by thrombin is probably different 
from that produced by C4b,2a,3b because thrombin cleavage of C5 does not result in 
the production of anaphylatoxin activity (24).  The presence of C3b adjacent  to the 
C4b,2a complex modifies the specificity of the complex from a C3 convertase to a C5 
convertase. It is, therefore, tempting to speculate that the C3b molecule adjacent  to 
the thrombin molecule on the platelet membrane modifies the specificity of thrombin 
from a C3 convertase to a C5 convertase. 
Because thrombin can activate platelets by different mechanisms, it was of interest 
to  determine  which  mechanism  was  involved  in  the  complement  enhancement. 
Aspirin and indomethacin  are both inhibitors of the enzyme cyclo-oxygenase of the 
arachidonic acid transformation pathway. When platelets were pretreated with these 
drugs,  only aspirin  led  to the  inhibition  of complement-enhanced  aggregation  and 
release of serotonin.  However, when the drugs were present in the reaction mixture, 
both  inhibited  the  effect.  Ingestion  of aspirin  by  the  donor  of the  platelets  also 
inhibited  the complement effect. Thus, it appears that thrombin-mediated comple- 
ment-dependent  aggregation  and  release of serotonin  acts via the arachidonie  acid 
transformation pathway. The mechanism by which cell-bound C5b-9 may influence 
cyclo-oxygenase activity remains to be determined. 
Summary 
Thrombin-mediated platelet aggregation and release is enhanced  by the presence 
of C3, C5, C6, C7, C8, and C9 of human complement. The interaction of thrombin 
with its receptor on the platetet membrane initiates activation of complement on the 
platelet surface. Trypsin-mediated platelet function is not enhanced by the addition 
of complement, probably because trypsin has no receptor on the platelet surface so 
activation  of complement  is  triggered  in  the  fluid  phase  and  not  on  the  platelet 
surface.  Activation of complement by thrombin  led  to production  of dimers of the 
C5b-9 complex on the platelet surface. These complexes were eluted from the platelet 
membrane and were identified physicochemically and morphologically. 
The mechanism of complement-induced  enhancement  of platelet  function  is not 
clear,  however,  it  probably  is  mediated  via  the  arachidonic  acid  transformation 
pathway because this activity was blocked by known  inhibitors  of cyclo-oxygenase, 
namely, aspirin and indomethacin. 
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